How long should a patient with alcohol withdrawal stay on Keppra (levetiracetam) after being treated with benzodiazepines (BZD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Keppra (Levetiracetam) After Alcohol Withdrawal Treatment

Keppra (levetiracetam) should be discontinued after successful treatment of alcohol withdrawal with benzodiazepines, as there is no evidence supporting its continued use for alcohol withdrawal management.

Evidence on Keppra in Alcohol Withdrawal

The available evidence does not support the use of levetiracetam (Keppra) as either a primary or maintenance therapy for alcohol withdrawal syndrome:

  • A multicenter, prospective, randomized, placebo-controlled trial found that levetiracetam did not significantly reduce alcohol withdrawal symptoms or decrease the need for benzodiazepines as rescue medication compared to placebo 1.
  • A retrospective study examining levetiracetam as adjunctive therapy concluded that it does not significantly reduce benzodiazepine requirements in patients experiencing alcohol withdrawal symptoms in the inpatient setting 2.

Standard of Care for Alcohol Withdrawal

Benzodiazepines remain the standard of care for alcohol withdrawal management:

  • Benzodiazepines are the preferred pharmacological agents for treatment of acute alcohol withdrawal 3.
  • The American College of Critical Care Medicine recommends benzodiazepines as the standard treatment for alcohol withdrawal syndrome, with treatment decisions guided by standardized assessment tools like CIWA-Ar 4.
  • For patients with decompensated liver disease, short-acting benzodiazepines (oxazepam or lorazepam) are typically recommended to avoid drug accumulation 5.

Duration of Therapy

  • Benzodiazepines should be administered during the acute withdrawal phase and then discontinued once withdrawal symptoms have resolved.
  • According to clinical practice guidelines, benzodiazepines administered for alcohol withdrawal should be weaned over several days to reduce the risk of drug withdrawal 5.
  • The French Association for the Study of the Liver and the French Alcohol Society guidelines recommend that benzodiazepine treatment for alcohol withdrawal should only be given if necessary and continued until symptoms disappear 5.

Alternatives to Benzodiazepines

For patients who may not respond well to benzodiazepines or have contraindications:

  • Carbamazepine (200 mg every 6-8 hours) can be effective for seizure prevention and as an alternative to benzodiazepines 4.
  • For benzodiazepine-refractory delirium tremens, phenobarbital, propofol, and dexmedetomidine may be considered as alternative or adjunctive therapies 4, 6.

Long-term Management After Withdrawal

After successful withdrawal management:

  • Focus should shift to preventing relapse through medications such as acamprosate, naltrexone, or disulfiram 4.
  • Refer patients to specialized addiction services and mutual help groups like Alcoholics Anonymous 4.
  • Consider psychiatric consultation for evaluation, treatment planning, and long-term abstinence planning 4.

Conclusion

There is no evidence supporting the continued use of Keppra (levetiracetam) after successful treatment of alcohol withdrawal with benzodiazepines. Benzodiazepines should be tapered and discontinued once withdrawal symptoms have resolved, and focus should shift to long-term management strategies for alcohol use disorder.

References

Research

Benzodiazepine treatment for alcohol-dependent patients.

Alcohol and alcoholism (Oxford, Oxfordshire), 1998

Guideline

Alcohol Withdrawal Syndrome Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of Severe Alcohol Withdrawal.

The Annals of pharmacotherapy, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.